Evaluation of the efficacy of romosozumab for glucocorticoid-induced osteoporosis in initial glucocorticoid administration patients
Not Applicable
Recruiting
- Conditions
- glucocorticoid-induced osteoporosis
- Registration Number
- JPRN-UMIN000037239
- Lead Sponsor
- Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have received romosozumab or denosumab or bisphosphonate 2. Patients with contraindication for romosozumab or denosumab or bisphosphonate 3. Patients with severe renal dysfunction (eGFR < 30mL/min/1.73m2) 4. Patients who is currently pregnant, breastfeeding or willing to get pregnant 5. Patients who do not give consent to the study 6. Patients who are judged to be inappropriate by the physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of bone mineral density at 12 months after initiation of glucocorticoid therapy
- Secondary Outcome Measures
Name Time Method The change of bone mineral density at 36 months after initiation of glucocorticoid therapy, the change of bone metabolism markers and adverse events during the observation period